SG11201704651UA - Pyridazinone macrocycles as irak inhibitors and uses thereof - Google Patents
Pyridazinone macrocycles as irak inhibitors and uses thereofInfo
- Publication number
- SG11201704651UA SG11201704651UA SG11201704651UA SG11201704651UA SG11201704651UA SG 11201704651U A SG11201704651U A SG 11201704651UA SG 11201704651U A SG11201704651U A SG 11201704651UA SG 11201704651U A SG11201704651U A SG 11201704651UA SG 11201704651U A SG11201704651U A SG 11201704651UA
- Authority
- SG
- Singapore
- Prior art keywords
- macrocycles
- pyridazinone
- irak inhibitors
- irak
- inhibitors
- Prior art date
Links
- -1 Pyridazinone macrocycles Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562112793P | 2015-02-06 | 2015-02-06 | |
| PCT/US2016/016708 WO2016127024A1 (en) | 2015-02-06 | 2016-02-05 | Pyridazinone macrocycles as irak inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201704651UA true SG11201704651UA (en) | 2017-07-28 |
Family
ID=55436166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201704651UA SG11201704651UA (en) | 2015-02-06 | 2016-02-05 | Pyridazinone macrocycles as irak inhibitors and uses thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9624246B2 (en) |
| EP (1) | EP3253763B1 (en) |
| JP (1) | JP6920202B2 (en) |
| KR (1) | KR102551597B1 (en) |
| CN (1) | CN107428765B (en) |
| AU (1) | AU2016215184B2 (en) |
| BR (1) | BR112017014970B1 (en) |
| CA (1) | CA2970550C (en) |
| ES (1) | ES2841452T3 (en) |
| IL (1) | IL253519B (en) |
| MX (1) | MX380929B (en) |
| RU (1) | RU2708066C2 (en) |
| SG (1) | SG11201704651UA (en) |
| WO (1) | WO2016127024A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2970550C (en) * | 2015-02-06 | 2023-09-19 | Merck Patent Gmbh | Pyridazinone macrocycles as irak inhibitors and uses thereof |
| TWI808055B (en) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-1 inhibitors |
| TWI794171B (en) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-l1 inhibitors |
| JOP20180011A1 (en) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | Perulo derivatives [1, 2-b] pyridazine |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| WO2019120267A1 (en) * | 2017-12-22 | 2019-06-27 | 成都先导药物开发股份有限公司 | Imidazo[1,2-b]pyridazine macrocyclic kinase inhibitor |
| MX2020009234A (en) * | 2018-04-05 | 2020-10-12 | Merck Patent Gmbh | Heteroaryl compounds as type ii irak inhibitors and uses hereof. |
| TWI842978B (en) | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | Pyrrolo[1,2-b]pyridazine derivatives |
| JP7169429B2 (en) | 2018-08-13 | 2022-11-10 | ギリアード サイエンシーズ, インコーポレイテッド | Pyrrolo[1,2-b]pyridazine derivatives as IRAK4 inhibitors |
| TWI727392B (en) | 2018-08-13 | 2021-05-11 | 美商基利科學股份有限公司 | Thiadiazole irak4 inhibitors |
| KR102659550B1 (en) | 2018-08-13 | 2024-04-23 | 길리애드 사이언시즈, 인코포레이티드 | Pyrrolo[1,2-B]pyridazine derivatives as IRAK4 inhibitors |
| US11998534B2 (en) * | 2020-02-12 | 2024-06-04 | Eubulus Biotherapeutics Inc. | GPX4 inhibitor in combination with anticancer agent for treating proliferative disease |
| CN111603471B (en) * | 2020-06-24 | 2021-07-09 | 山东省科学院生物研究所 | Use of an o-diaza heterocyclic compound in the preparation of a medicine for inhibiting TLR4 receptors |
| WO2022070287A1 (en) * | 2020-09-30 | 2022-04-07 | 旭化成ファーマ株式会社 | Macrocycle compound |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000247959A (en) * | 1999-02-26 | 2000-09-12 | Kowa Co | Pyridazin-3-one derivatives and pharmaceuticals containing the same |
| JP2010138073A (en) * | 2007-03-30 | 2010-06-24 | Taisho Pharmaceutical Co Ltd | Picolinic acid amide compound |
| US8703768B2 (en) * | 2010-06-09 | 2014-04-22 | Hoffmann-La Roche Inc. | Nitrogen containing heteroaryl compounds |
| US9586948B2 (en) * | 2012-10-08 | 2017-03-07 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
| LT2953952T (en) * | 2013-02-07 | 2017-08-25 | Merck Patent Gmbh | Macrocyclic pyridazinone derivatives |
| RS56331B1 (en) * | 2013-02-07 | 2017-12-29 | Merck Patent Gmbh | Pyridazinone-amides derivatives |
| CA2970550C (en) * | 2015-02-06 | 2023-09-19 | Merck Patent Gmbh | Pyridazinone macrocycles as irak inhibitors and uses thereof |
-
2016
- 2016-02-05 CA CA2970550A patent/CA2970550C/en active Active
- 2016-02-05 BR BR112017014970-2A patent/BR112017014970B1/en not_active IP Right Cessation
- 2016-02-05 AU AU2016215184A patent/AU2016215184B2/en not_active Ceased
- 2016-02-05 CN CN201680018681.1A patent/CN107428765B/en not_active Expired - Fee Related
- 2016-02-05 WO PCT/US2016/016708 patent/WO2016127024A1/en not_active Ceased
- 2016-02-05 MX MX2017009624A patent/MX380929B/en unknown
- 2016-02-05 RU RU2017130761A patent/RU2708066C2/en active
- 2016-02-05 SG SG11201704651UA patent/SG11201704651UA/en unknown
- 2016-02-05 ES ES16706471T patent/ES2841452T3/en active Active
- 2016-02-05 KR KR1020177020262A patent/KR102551597B1/en active Active
- 2016-02-05 EP EP16706471.6A patent/EP3253763B1/en active Active
- 2016-02-05 JP JP2017539435A patent/JP6920202B2/en not_active Expired - Fee Related
- 2016-02-05 US US15/016,584 patent/US9624246B2/en not_active Expired - Fee Related
-
2017
- 2017-03-06 US US15/450,463 patent/US10517872B2/en active Active
- 2017-07-17 IL IL253519A patent/IL253519B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| IL253519A0 (en) | 2017-09-28 |
| AU2016215184A1 (en) | 2017-06-29 |
| CA2970550C (en) | 2023-09-19 |
| MX2017009624A (en) | 2017-11-20 |
| IL253519B (en) | 2021-01-31 |
| KR102551597B1 (en) | 2023-07-05 |
| EP3253763B1 (en) | 2020-09-30 |
| US9624246B2 (en) | 2017-04-18 |
| ES2841452T3 (en) | 2021-07-08 |
| HK1246287A1 (en) | 2018-09-07 |
| NZ732527A (en) | 2022-03-25 |
| US20170173019A1 (en) | 2017-06-22 |
| RU2017130761A (en) | 2019-03-06 |
| CN107428765B (en) | 2020-12-29 |
| US20160229871A1 (en) | 2016-08-11 |
| MX380929B (en) | 2025-03-12 |
| RU2708066C2 (en) | 2019-12-04 |
| WO2016127024A1 (en) | 2016-08-11 |
| RU2017130761A3 (en) | 2019-07-17 |
| KR20170113551A (en) | 2017-10-12 |
| JP2018505166A (en) | 2018-02-22 |
| CA2970550A1 (en) | 2016-08-11 |
| US10517872B2 (en) | 2019-12-31 |
| CN107428765A (en) | 2017-12-01 |
| BR112017014970A2 (en) | 2018-03-27 |
| BR112017014970B1 (en) | 2022-11-16 |
| EP3253763A1 (en) | 2017-12-13 |
| JP6920202B2 (en) | 2021-08-18 |
| AU2016215184B2 (en) | 2020-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265922A (en) | Tyk2 inhibitors and uses thereof | |
| IL266109A (en) | Tyk2 inhibitors and uses thereof | |
| SG11201704651UA (en) | Pyridazinone macrocycles as irak inhibitors and uses thereof | |
| IL258180B (en) | Heterocyclic compounds and uses thereof | |
| ZA201801056B (en) | Heteroaryl compounds as irak inhibitors and uses thereof | |
| ZA201800975B (en) | Heteroaryl compounds as irak inhibitors and uses thereof | |
| IL291267A (en) | Jak1 selective inhibitors and uses thereof | |
| ZA201702402B (en) | Heteroaryl compounds as irak inhibitors and uses thereof | |
| EP3134091A4 (en) | Irak inhibitors and uses thereof | |
| GB201605126D0 (en) | Inhibitors and their uses | |
| EP3110820A4 (en) | Tyk2 inhibitors and uses thereof | |
| SG11201706029VA (en) | Anti-senescence compounds and uses thereof | |
| ZA201801548B (en) | Cyano thienotriazolodiazepines and uses thereof | |
| SG10201911204WA (en) | Autotaxin inhibitors and uses thereof | |
| IL263949A (en) | Complement inhibitors and uses thereof | |
| IL297057B2 (en) | Combinations and uses thereof | |
| ZA201705456B (en) | Benzoxaborole compounds and uses thereof | |
| IL254916A0 (en) | Inhibitors and their uses | |
| SG11201705907XA (en) | Mir-92 inhibitors and uses thereof | |
| IL255530A (en) | Efflux-pump inhibitors and therapeutic uses thereof | |
| GB201504763D0 (en) | Compounds and uses | |
| IL254241A0 (en) | Etv2 and uses thereof | |
| IL253459B (en) | Isoergoline compounds and uses thereof | |
| GB201718875D0 (en) | Autophagy-inhibiting compounds and uses thereof | |
| GB2543375B (en) | Compounds and their uses |